⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACXP News
Acurx Pharmaceuticals, Inc. Common Stock
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
prnewswire.com
ACXP
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of
prnewswire.com
ACXP
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
prnewswire.com
ACXP
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
prnewswire.com
ACXP
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
accessnewswire.com
ACXP
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
prnewswire.com
ACXP
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
prnewswire.com
ACXP
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
prnewswire.com
ACXP
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit Ready to Announce with Confidence?
newsfilecorp.com
ACXP
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
accessnewswire.com
VTIX
NTHI
MDCX
YYGH
VVOS
DVLT
ACXP
IGC
CAST